VAXCYTE INC. - COMMON STOCK

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

04 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 فبراير 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

15 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 فبراير 2024 17:39:14 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 فبراير 2024 15:05:49 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $750 Million Public Offering

30 يناير 2024 22:37:41 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

30 يناير 2024 15:01:28 بحسب Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

29 يناير 2024 07:30:33 بحسب Nasdaq GlobeNewswire

Vaxcyte Appoints Whitney Jones as Chief People Officer

16 يناير 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

04 يناير 2024 15:01:42 بحسب Nasdaq GlobeNewswire

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

04 ديسمبر 2023 17:35:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Appoints Jacks Lee to Board of Directors

28 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

27 نوفمبر 2023 15:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

09 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

06 نوفمبر 2023 15:03:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

31 أكتوبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

19 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

16 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

19 سبتمبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

08 أغسطس 2023 15:03:00 بحسب Nasdaq GlobeNewswire